Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Reports $11.2M Second-Quarter Gain

NEW YORK, July 21 (GenomeWeb News) - Affymetrix today posted total revenues of $79.8 million for the second quarter of 2004, compared to $68.6 million for Q2 of 2003.

 

The company said that $1.4 million of its second-quarter revenue was related to the sales of products and wafers to Perlegen Sciences. In Q2 of 2003, Affymetrix said that $2.8 million of its revenue was related to Perlegen sales.

 

Affymetrix reported revenues of $35.4 million on sales of its GeneChip microarrays and $20.1 million on instruments. The company said it increased its installed base of GeneChip systems to approximately 1,070.

 

The company also reported a net income of $7 million in Q2 of 2004, as compared to $5.2 million in the same quarter last year. R&D expenditures rose to $17.8 million for the second quarter from $16.6 million in Q2 of 2003.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.